The Patent Finder
KB

Kyntra Bio, Inc.

First filing 2003
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Fibrogen, Inc. (to 2026)

19 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Jan 2027
Next term end
10
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase US 8,921,389
Cited by 57 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Ends Feb 2032 · High confidence
Also notable
Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof US 7,863,292
Cited by 48 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Ends Jan 2027 · Medium confidence
Also notable
Crystalline Forms of a Prolyl Hydroxylase Inhibitor US 9,115,085
Cited by 24 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Ends Jul 2033 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 25, 2027
    The maintenance fee for Crystalline Forms of a Prolyl Hydroxylase Inhibitor (US 9,115,085) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
  • 1 fee due Sep 1, 2027
    The maintenance fee for Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase (US 9,271,970) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
  • 1 fee due Nov 17, 2027
    The maintenance fee for Process for Making Isoquinoline Compounds (US 9,340,511) comes due Nov 17, 2027. Unpaid by May 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The largest of its 10 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,863,292Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 8,318,703Methods for Improving Kidney Function
In force
 · Medium confidence
In forceMedium confidence
US 7,696,223Pyrrolo- and Thiazolo-Pyridine Compounds, and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 7,928,120Cyanoisoquinoline Compounds and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 8,088,381Methods of Treatment of Cardiovascular Disease Using Anti-Ctgf Agents
In force
 · High confidence
In forceHigh confidence
US 8,921,389Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase
In force
 · High confidence
In forceHigh confidence
US 9,271,970Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase
In force
 · High confidence
In forceHigh confidence
US 9,695,170Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase
In force
 · High confidence
In forceHigh confidence
US 9,409,8924 -Hydroxy- Isoquinoline Compounds as Hif Hydroxylase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 8,883,823Crystalline Forms of a Prolyl Hydroxylase Inhibitor
In force
 · High confidence
In forceHigh confidence
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
Also on record, not counted in the 19: 5 patents ended · 1 application pending. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited